一决雌雄的本钱。(生物谷Bioon.com)
完整说明书附件：https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287
参考文献：
1、 （i）Margolin K， Ernstoff MS， Hamid O， et al. Ipilimumab in patients with melanoma and brain metastases： an open-label， phase 2 trial. Lancet Oncol 2012；13：459-465. (ii) Weber JS， Kahler KC， Hauschild A. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. J Clin Oncol 2012. (iii) Hodi FS， O’Day SJ， McDermott DF， Weber RW， et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010；363：711-723. (iv) Robert C， Thomas L， Bondarenko I， et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011；364：2517-2526.
2、 （i）Sosman JA， Kim KB， Schuchter L， et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012；366：707-714. (ii) Chapman PB， Hauschild A， Robert C， et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011；2507-2516.
3、 Hauschild A， Grob JJ， Demidov LV， et al. Dabrafenib in BRAFmutated metastatic melanoma： a multicentre， open-label， phase 3 randomised controlled trial. Lancet 2012；380：358-365.
4、 Flaherty KT， Infante JR， Daud A， et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Eng J Med 2012；367：1694-1703.
5、 (i) Rosenberg SA， Yang JC， Topalian SL， et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994；271：907-913. (ii) Atkins MB， Lotze MT， Dutcher JP， et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma： analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999；17：2105-2116. (iii) Atkins MB， Kunkel L， Sznol M， Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma： long-term survival update. Cancer J Sci Am 2000；6 Suppl 1：S11-14. (iv) Smith FO， Downey SG， Klapper JA， et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008；14(17)：5610-5618.
6、 Flaherty KT， Robert C， Hersey P， et al. Improved Survial with MEK Inhibition in BRAF-mutated melanoma. N Eng J Med 2012；367：107-114.
7、 Carvajal RD， Antonescu CR， Wolchok， JD， et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011；395：2327-2334.
8、 Middleton MR， Grob JJ， Aaronson N， et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000；18：158-166.
9、 Serrone L， Zeuli M， Sega FM， et al. Dacarbazine-based chemotherapy for metastatic melanoma： thirty-year experience overview. J Exp Clin Cancer Res 2000；19：21-34.
10、 Hersh EM， O'Day SJ， Ribas A， et al. A phase 2 Clinical trial of nab-Paclitaxel in previously treated and chemotherapy-na？ve patients with metastatic melanoma. Cancer 2010；116：155-163. (ii) Kottschade LA， Suman VJ， Amatruda T， et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage iv melanoma： a north central cancer treatment group study， N057E(1). Cancer 2011；117：1704-1710.
11、 Wiernik PH and Einzig AI. Taxol in malignant melanoma. J Natl Cancer Inst Monogr 1993；15：185-187.
12、 (i) Legha SS， Ring S， Eton O， et al. Development of a biochemotherapy regimen with concurrent administration of |
